Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SGT-501, the Company’s novel, AAV-based investigational gene therapy for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT).
Technical Toolboxes Announces Strategic Growth Investment From BVP Forge To Accelerate Innovation in Energy Infrastructure Software
UF startup Technical Toolboxes, a leading provider of advanced engineering and maintenance software for energy infrastructure, announced a strategic growth investment from BVP Forge.
SandboxAQ and iOncologi Partner To Accelerate Brain Cancer Treatment With AI-Driven Drug Discovery for Glioblastoma
SandboxAQ and UF startup iOncologi have announced a strategic collaboration to co-develop, validate, and commercialize a novel high-fidelity mRNA vaccine targeting glioblastoma—the most common and aggressive malignant brain tumor in adults.
Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy To Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Solid Biosciences, which acquired UF startup AavantiBio, announced FDA and Health Canada approval to begin clinical trials of SGT-501, a gene therapy targeting CPVT, a severe heart rhythm disorder caused by RYR2 mutations.
Atsena Therapeutics Announces Alignment With FDA on Regulatory Pathway to Approval for ATSN-201 in X-Linked Retinoschisis (XLRS)
UF startup Atsena Therapeutics received FDA approval to expand its Phase 1/2 LIGHTHOUSE study of ATSN-201 into a pivotal Phase 1/2/3 trial to support a BLA submission for treating X-linked retinoschisis (XLRS).
TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (Pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, formed by CohBar and Morphogenesis, a UF startup, has announced the initiation of its Phase 3 accelerated approval trial of IFx-2.0, TuHURA's lead innate immune agonist, in patients with advanced or metastatic Merkel cell carcinoma (MCC).
LightPath Debuts First Industrial-Grade Cooled Optical Gas Imaging Camera
UF startup LightPath Technologies announced that its subsidiary, G5 Infrared, has launched its first industrial-grade MWIR optical gas imaging camera, following a successful test at a certified facility.
Myosin Therapeutics Receives FDA Clearance To Initiate First-in-Human Trial of MT-125 in Glioblastoma
UF startup Myosin Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for MT-125.
Florida Venture Forum Announces Startups Selected to Present at 2025 Florida Early Stage Venture Conference
Oboro Labs, a UF startup, is among the companies selected to pitch at the 2025 Florida Early Stage Venture Conference, showcasing the innovative technologies emerging from UF’s entrepreneurial ecosystem.
Tech Tuesday: University of Florida Startup Is Changing How Students Connect With Classmates
In this week’s Tech Tuesday, UF Innovate host Bethany Gaffey introduces CourseLynx, a UF startup transforming how students connect on campus and in class.
